Investor Presentaiton

Limitations of Other Approaches Viral Vectors - Receptor/cell target based mediated entry • Systemic delivery/local injection. • Preexisting or induced immunity is an issue • Biologic variability of take Immune bias tuned by vector • Hard to re-administer/tissue tropism limits and positives RNA LNP/nanoparticle delivery dependent • - Systemic delivery, localized expression (liver>lung or spleen) Process for manufacture and release work in progress Formulations + RNA follow tissue targeting of the particles/cold chain required, include focus on IV route • DLT observed, low CTL induced, inflammatory 49 49 • High cost of goods double- stranded DNA 0000000 fiber hexon DNA 3030000 penton base penton C single-stranded DMA exon intron RNA Sequence INOVIO POWERING DNA MEDICINES

View entire presentation